On Wednesday, Gilead CEO John Milligan shared some clues into what might be next for the ailing drugmaker.

When the week began, Stada had plenty of interested suitors, but it wasn’t sure any of them would make a real offer. Now, the first has come in at $3.72…

Allergan CEO Brent Saunders has said it before, and he’ll say it again: He’s not interested in buying Valeant.

Pharma execs and boards essentially pressed pause on dealmaking as 2016 came to a close, with uncertainties about the U.S. presidential election—and a Donald…

Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

​​​​​​​Gilead might not enjoy suffering its recent, severe hep C revenue downfall, but according to one analyst, the rest of biopharma stands to benefit from…

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Stada said it has a third suitor in the mix to buy the company, and Bernstein analyst Ronny Gal thinks he may know who it is.

Stada already had two interested buyers in the mix as of earlier this week. And now, it’s got three.

M&A